Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo's Tresiba Significantly Reduces Hypoglycemia Versus Lantus In DEVOTE

Executive Summary

Novo Nordisk's Tresiba reduced the risk of severe hypoglycemia in type 2 diabetes by 40% compared to Sanofi's standard-of-care insulin Lantus. The data may convince physicians to prescribe longer acting insulins, but their effect on formulary positioning remains to be seen.

Advertisement

Related Content

Novo Nordisk CEO Hopes Tresiba Can Re-Enter Germany On A Higher Price
Can Sanofi’s Toujeo Prickle Tresiba In India?
ADA 2017: Outlook For New Longer Acting Insulins Amid US Pricing Sensitivity
Considering The Value Of Cardiovascular Data And Real World Evidence In Diabetes
Novo's CSO Has A Lifetime Product Plan For Diabetes Patients

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098926

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel